Mark Voigt

Agathos was pleased to welcome Mark in January 2022 as the fifth member of its growing team.  Joining a small company with ambitious goals required him to come up to speed quickly.  “I am excited to be a part of Agathos and create ethically-developed products and services for genetic medicine and biotechnology,” said Voigt.  “It has been an intense first few months during which I have immersed myself in the science and strategy of the company.  I’m committed to working with the talented founders and team members to create innovative solutions that will positively impact patients, researchers, and healthcare providers.”

Voigt was Director, General and Vascular Surgery at St. Cloud Hospital – CentraCare where he was responsible for physician recruitment and contracting as well as developing new service lines for the health system.  Prior to that, he was Key Account Manager at R&D Systems where he worked with scientists, lab managers, and directors to identify products and services to meet their experimental needs for drug discovery, biomarker screening, and translational research.

“Each team member at Agathos must work across functions in a fast-paced environment.  Mark has already made significant contributions in a variety of areas, from lab management and procurement to evaluating technology and market opportunities,” said James Brown, CEO of Agathos.  “His diverse background in biotechnology sales, product development, and healthcare management brings a set of skills that are important for our success.  Mark’s energy and enthusiasm is infectious and has a positive impact on everyone.”

The addition of Mark’s role, the recent addition of laboratory and office space, and the recruiting of new scientist and research associate positions are part of the company’s plan for continued growth in 2022.  “The founders of Agathos are dedicated to developing new, ethically-developed tools and therapies for genetic medicine and look forward to growing the company to achieve these goals,” added Brown.

Agathos laboratory in the Comstock research center, formerly the PRACS building

Feb. 23, 2022 (FARGO, N.D.) – Agathos Biologics announced today that it has signed a lease with Comstock Companies to acquire additional laboratory and office space, bringing its total to 10,000 square feet of usable space.  “We are excited to expand our footprint in Fargo, North Dakota, which continues to see growth in its biotechnology industry,” said James Brown, CEO of Agathos.  “The space is purpose-built for laboratory research, which will allow us to immediately increase our capacity to support our pipeline of projects.”

“We are pleased to see the growth of Agathos, adding to the space leased by life science tenants, including Sanford Health and Immunoprecise, in our research center, the former PRACS building,” said Scott Kjos, Managing Partner of Comstock Companies.  “We are eager to support the growing biotechnology industry in Fargo and adding facilities and infrastructure that will enable these companies to have a positive impact on human health.”

Founded by James Brown, John Ballantyne, and Michael Chambers, Agathos Biologics is pursuing opportunities in gene therapy, nucleic acid and protein delivery, and biomanufacturing.  Agathos’ mission as The Good Science Company is creation of transformative technologies benefiting patients, physicians, and researchers that are developed ethically, avoiding biological materials from sources including human embryonic stem cells and aborted fetal tissue and procuring materials with proper consent.

“The founders of Agathos believe that the explosive growth of biotechnology enables us to provide ethical alternatives to existing biomaterials that will allow us all to live healthier lives without compromising our deeply held beliefs.  We look forward to leading this new approach and working within the industry to realize this vision,” added Brown.

About Agathos

Agathos Biologics is a biotechnology company pursuing transformational science in biomanufacturing, biologic payload delivery, and cell and gene therapy. Discoveries in bioprocessing and genetic characterization and control have created an abundance of scientific possibilities that can help us all lead better lives. Our mission as the good science company is to create breakthrough products and services within a strong ethical and moral framework that benefits everyone. We believe in science that serves and have a relentless focus on serving our clients, employees, and society. For more information, please visit www.agathos.bio.

About Comstock

Comstock Companies provides its customers with leasable space for office, research, commercial, and industrial needs in the tri-state area. Our mission is to serve our customers with the service they deserve.

August 30, 2021 (FARGO, N.D.) – Agathos Biologics, a biotechnology company developing transformational science within a strong ethical and moral framework, today announced the company has been awarded $900,000 from the North Dakota Department of Agriculture Bioscience Innovation Grant (BIG) Program.  Agriculture Commissioner Doug Goehring announced that nine grants have been awarded totaling $4.9 million to foster the growth of the bioscience industry in North Dakota.  “Advances in bioscience have already transformed many sectors including agriculture and medicine,” Goehring said. “These grants will help North Dakota stay on the forefront of bioscience innovation.”

Agathos Biologics’ project funded by ND BIG will focus on challenges that limit patient access to advanced genetic medicines that can significantly impact quality of life—cost, availability, and ethical concerns. Company scientists will create new materials and methods for research and biomanufacturing and use them for drug development, which will address unmet medical needs and increase the availability of genetic medicines to more patients. The company will make these products and services available to the broader biotechnology industry through direct sales and licensing, partnerships, and collaborations.

“We are honored to receive this support from the State of North Dakota and thank the Commissioner and the Committee for their work on behalf of the citizens of the state,” said James Brown, Chief Executive Officer of Agathos Biologics.  “We founded the company in North Dakota because its business-friendly environment, skilled workforce, and growing biotechnology ecosystem make it an ideal place to expand the company and achieve our goal to develop genetic medicine products and services that positively impact human health and are ethically acceptable to all.”

August 26, 2021 (FARGO, N.D.) – As we seek to build Agathos Biologics, it’s important to state our mission, values and strategy. We have taken the first step in this direction, describing our approach on our web site in the pages “Our Mission”, “Our Strategy” and “Good Science for a Better World” (collectively GSBW). We will look for opportunities to refine and further communicate in these areas, and one way to do this is to respond to relevant current events. Recently, Jason Fried, CEO of the software company Basecamp made a public statement about “Changes at Basecamp” and CTO David Hansson followed up with a post titled “new etiquette regarding societal politics at work”, which have garnered considerable news coverage and responses from many different perspectives. We believe Basecamp’s statement raises some important issues that we would like to address in the context of the culture of Agathos Biologics. Read the white paper in full here.

Press release

Jagadish Loganathan

May 26, 2021 (FARGO, N.D.) – Agathos Biologics, a biotechnology company developing transformational science in biomanufacturing, biologic payload delivery, and cell and gene therapy within a strong ethical and moral framework, today announced the appointment of Jagadish Loganathan, Ph.D. as Director, Research and Development.  Loganathan’s responsibilities include establishing research and development operations at Agathos’ Fargo, North Dakota facilities, recruiting and managing scientific staff, and leading internal and external programs.

Prior to joining Agathos Loganathan was a Scientist at the Indiana University School of Medicine where he studied the importance of the correct compartmentalization of different molecular signals mediated by natural compounds targeting cancer genes.  His scientific experience includes work as a research associate at North Dakota State University (NDSU) targeting cancer cells in a hypoxic environment using nanoparticles and the molecular mechanism and pathophysiology of bronchial asthma in the different sexes.  Previously as a postdoctoral fellow at NDSU he studied the chemotherapeutic effects of plant-derived small molecules and lentiviral vectors on pancreatic and lung cancer cells. Loganathan received his Ph.D. in microbiology from the University of Madras in Chennai, India.

“We are pleased to have Jagadish join Agathos during this critical time as we build our research and development capabilities and team,” said James Brown, CEO.  “His accomplishments and experience in molecular biology, cell culture, and microbiology will enable him to effectively lead our efforts to develop new materials and methods for biomanufacturing and use them in our therapeutic programs.”

“I am excited to bring my skills and expertise to Agathos Biologics and pursue our mission as the good science company,” said Loganathan.  “Our novel biomanufacturing and therapeutic products will provide scientific and medical benefits without ethical concerns about the origin or source of materials used in their development.  I look forward to using my experiences building laboratory operations and mentoring others to quickly establish Agathos as a leader in ethical biotechnology.”